Fluoroquinolones in the treatment of cystic fibrosis

N Høiby; S S Pedersen; T Jensen; N H Valerius; C Koch

doi:10.2165/00003495-199300453-00017

Fluoroquinolones in the treatment of cystic fibrosis

N Høiby, S S Pedersen, T Jensen, N H Valerius, C Koch

10 Citations (Scopus)

Abstract

Cystic fibrosis patients suffer from recurrent and chronic lung infections mainly caused by Staphylococcus aureus, Haemophilus influenzae and Pseudomonas aeruginosa. The fluoroquinolones, notably ciprofloxacin and ofloxacin, represent an important addition to the therapy of P. aeruginosa infections. They offer the possibility of effective oral treatment for early colonisation as well as chronic infections, even in children. They are associated with only few and mild adverse effects. Development of resistance represents an increasing problem.

Original language	English
Journal	Drugs
Volume	45 Suppl 3
Pages (from-to)	98-101
Number of pages	4
ISSN	0012-6667
DOIs	https://doi.org/10.2165/00003495-199300453-00017
Publication status	Published - 1993
Externally published	Yes

Keywords

Ciprofloxacin/therapeutic use
Cystic Fibrosis/drug therapy
Drug Therapy, Combination
Humans
Ofloxacin/therapeutic use
Pseudomonas Infections/prevention & control

Access to Document

10.2165/00003495-199300453-00017

Cite this

@article{c9a05e780a834fdcb97fea2089ca6a7f,

title = "Fluoroquinolones in the treatment of cystic fibrosis",

abstract = "Cystic fibrosis patients suffer from recurrent and chronic lung infections mainly caused by Staphylococcus aureus, Haemophilus influenzae and Pseudomonas aeruginosa. The fluoroquinolones, notably ciprofloxacin and ofloxacin, represent an important addition to the therapy of P. aeruginosa infections. They offer the possibility of effective oral treatment for early colonisation as well as chronic infections, even in children. They are associated with only few and mild adverse effects. Development of resistance represents an increasing problem.",

keywords = "Ciprofloxacin/therapeutic use, Cystic Fibrosis/drug therapy, Drug Therapy, Combination, Humans, Ofloxacin/therapeutic use, Pseudomonas Infections/prevention \& control",

author = "N H{\o}iby and Pedersen, \{S S\} and T Jensen and Valerius, \{N H\} and C Koch",

year = "1993",

doi = "10.2165/00003495-199300453-00017",

language = "English",

volume = "45 Suppl 3",

pages = "98--101",

journal = "Drugs",

issn = "0012-6667",

publisher = "Adis",

}

TY - JOUR

T1 - Fluoroquinolones in the treatment of cystic fibrosis

AU - Høiby, N

AU - Pedersen, S S

AU - Jensen, T

AU - Valerius, N H

AU - Koch, C

PY - 1993

Y1 - 1993

N2 - Cystic fibrosis patients suffer from recurrent and chronic lung infections mainly caused by Staphylococcus aureus, Haemophilus influenzae and Pseudomonas aeruginosa. The fluoroquinolones, notably ciprofloxacin and ofloxacin, represent an important addition to the therapy of P. aeruginosa infections. They offer the possibility of effective oral treatment for early colonisation as well as chronic infections, even in children. They are associated with only few and mild adverse effects. Development of resistance represents an increasing problem.

AB - Cystic fibrosis patients suffer from recurrent and chronic lung infections mainly caused by Staphylococcus aureus, Haemophilus influenzae and Pseudomonas aeruginosa. The fluoroquinolones, notably ciprofloxacin and ofloxacin, represent an important addition to the therapy of P. aeruginosa infections. They offer the possibility of effective oral treatment for early colonisation as well as chronic infections, even in children. They are associated with only few and mild adverse effects. Development of resistance represents an increasing problem.

KW - Ciprofloxacin/therapeutic use

KW - Cystic Fibrosis/drug therapy

KW - Drug Therapy, Combination

KW - Humans

KW - Ofloxacin/therapeutic use

KW - Pseudomonas Infections/prevention & control

UR - https://www.scopus.com/pages/publications/0027328149

U2 - 10.2165/00003495-199300453-00017

DO - 10.2165/00003495-199300453-00017

M3 - Review

C2 - 7689459

SN - 0012-6667

VL - 45 Suppl 3

SP - 98

EP - 101

JO - Drugs

JF - Drugs

ER -

Fluoroquinolones in the treatment of cystic fibrosis

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this